All In Biotech

Company

Novo

Drugs filed under this Drugs@FDA sponsor name, and trials whose lead sponsor matches it. The same company may file under other names.

Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

10

9 still marketed

Novel approvals

5

Approvals since 2021

16

Originals and new uses

Phase 3 trials

368

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Wegovy new use Mar 19, 2026
  • Wegovy approved Dec 22, 2025
  • Wegovy new use Nov 21, 2025
  • Ozempic new use Oct 17, 2025
  • Wegovy new use Breakthrough therapyPriority reviewAug 15, 2025
  • Rivfloza new use OrphanMar 27, 2025
  • Ozempic new use Jan 28, 2025
  • Ozempic new use Dec 9, 2024
  • Wegovy new use Nov 27, 2024
  • Wegovy new use Priority reviewMar 8, 2024

Drugs in development (0)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline

No investigational drugs in Phase 2 or 3 trials under this sponsor name.

Recruiting Phase 3 trials

Largest first.

Marketed drugs (9)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.